Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Transave has received composition of matter patent (US Patent No 7,718,189) for liposomal aminoglycoside formulations including its lead compound, Arikace (liposomal amikacin for inhalation) from US Patent and Trademark Office. The patent will provide exclusivity for Arikace until October 1, 2026.
Subscribe to our email newsletter
Last year US Patent office granted another patent (US Patent No 7,544,369) covering Transave Arikace for the sustained release of antibiotic and once-daily treatment of Pseudomonas lung infections.
Tim Whitten, CEO of Transave, said: “The issuance of this composition of matter patent significantly strengthens the intellectual property estate around Arikace and represents a valuable asset for Transave.
“We are continuing to secure and expand our proprietary position for Arikace which has the potential to become an important treatment for cystic fibrosis (CF) patients with Pseudomonas lung infections, non-CF bronchiectasis patients with Pseudomonas lung infections, and patients with nontuberculous mycobacteria (NTM) lung infections. We look forward to moving to Phase 3 as soon as possible.”